Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclachaena xanthifolia pollen is an allergenic extract derived from the pollen of the giant sumpweed (also known as marsh-elder). It is a biologic product used primarily in clinical settings for the diagnosis of hypersensitivity and allergic reactions, specifically autumn hay fever. The extract works by eliciting an IgE-mediated cutaneous response during skin testing (prick or intradermal) in individuals sensitized to the allergens present in the pollen. It was first approved in the United States in 1941, with subsequent biological license applications (BLA101376 and BLA103888) maintaining its status as a diagnostic tool for identifying Asteraceae family allergies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclachaena xanthifolia pollen.